SCHEMBL12713214

SCHEMBL12713214

CCC(C=O)Cc1cc(Cl)ccc1C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ TP53 P04637 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ STS P08842 2/20 0.43
▸ DPP4 P27487 1/20 0.43
▸ CNR1 P21554 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ FNTA P49354 2/20 0.42
▸ FNTB P49356 2/20 0.42
▸ MAPT P10636 3/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12713229 0.89 GPR119 (0.50) SMN1; SMN2DPP4CNR1ALDH1A1LMNA
SCHEMBL14436423 0.88 SMN1; SMN2 (0.47) SMN1; SMN2TP53POLBSTSDPP4
SCHEMBL12713213 0.85 SMN1; SMN2 (0.47) SMN1; SMN2TP53POLBSTSDPP4
SCHEMBL12713212 0.84 TP53 (0.47) SMN1; SMN2TP53POLBSTSDPP4
SCHEMBL13948350 0.83 SMN1; SMN2 (0.45) SMN1; SMN2TP53POLBSTSDPP4
SCHEMBL13002965 0.82 SMN1; SMN2 (0.44) SMN1; SMN2TP53POLBSTSDPP4
SCHEMBL14401276 0.82 SMN1; SMN2 (0.47) SMN1; SMN2TP53POLBSTSCNR1
SCHEMBL12713201 0.81 SMN1; SMN2 (0.46) SMN1; SMN2TP53POLBSTSCNR1
SCHEMBL12713199 0.80 SMN1; SMN2 (0.45) SMN1; SMN2TP53POLBSTSCNR1
SCHEMBL12713217 0.79 CNR1 (0.42) SMN1; SMN2TP53POLBSTSDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2011-04-14 — — US disclosed
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2011-04-14 — — US disclosed
WO-2007115798-A1 SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086836-A1 Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators MC4R, MC5R, MC3R SMN1; SMN2 1344/4885TP53 3292/4885POLB 3338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback